Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Non-Current Liabilities (2016 - 2022)

Historic Total Non-Current Liabilities for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $16.2 million.

  • Aptevo Therapeutics' Total Non-Current Liabilities fell 7067.62% to $16.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $16.2 million, marking a year-over-year decrease of 7067.62%. This contributed to the annual value of $16.2 million for FY2022, which is 7067.62% down from last year.
  • As of Q4 2022, Aptevo Therapeutics' Total Non-Current Liabilities stood at $16.2 million, which was down 7067.62% from $55.4 million recorded in Q4 2021.
  • Aptevo Therapeutics' 5-year Total Non-Current Liabilities high stood at $55.4 million for Q4 2021, and its period low was $16.2 million during Q4 2022.
  • In the last 5 years, Aptevo Therapeutics' Total Non-Current Liabilities had a median value of $36.9 million in 2018 and averaged $37.0 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 4987.96% in 2021, then tumbled by 7067.62% in 2022.
  • Quarter analysis of 5 years shows Aptevo Therapeutics' Total Non-Current Liabilities stood at $36.9 million in 2018, then grew by 12.68% to $41.6 million in 2019, then dropped by 11.1% to $37.0 million in 2020, then skyrocketed by 49.88% to $55.4 million in 2021, then crashed by 70.68% to $16.2 million in 2022.
  • Its Total Non-Current Liabilities stands at $16.2 million for Q4 2022, versus $55.4 million for Q4 2021 and $37.0 million for Q4 2020.